



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Silver Spring MD 20993

October 13, 2020

Matthew Weinberg
The Weinberg Group LLC
A ProPharma Group Company
1129 20th ST NW, Suite 600
Washington, DC 20036

Sent via email to: project.support@weinberggroup.com

Dear Petitioner:

Your petition to the Commissioner of Food and Drug Administration requesting that the FDA declare that the drug products, Vasopressin Injection USP, 50 units/2.5 mL (2.5 mL/vial in a single dose vial) and 100 units/5 mL (5 mL/vial in a single dose vial), are suitable for submission as an ANDA was received by this office on 10/12/2020.

It was assigned docket number FDA-2020-P-2077. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter and in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Dynna Bigby
Supervisory Administrative Proceedings Officer
Dockets Management Staff
FDA/Office of Operations (OO)